Medicamen Biotech

₹280.95As of Sun 8 Nov 2026, 12:00 UTC

NSE:MEDICAMEQHealthcare

Country India

PE (Fwd) 33.67

TSR 5Y CAGR (12.78%)

Div yield 0.36%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.79

PE TTM 39.52

TSR TTM (25.13%)

Mkt cap ₹3.777B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹312

11.09%

(73.24%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

1.978

Revenue₹B

—

1.154

1.409

1.793

1.675

1.978

2.177

14.41%

18.04

Revenue growth%

—

22.02

27.29

(6.56)

18.04

10.09

20.03

—

47.15

Gross margin%

—

53.05

47.86

47.52

48.38

47.15

46.99

47.86

6.25

Operating margin%

—

15.50

12.52

8.51

7.04

6.25

6.16

8.51

4.88

Net margin%

—

12.90

10.54

6.10

4.24

4.88

4.80

6.10

39.52

P/E ratio (avg)x

—

66.00

75.32

67.62

92.29

51.47

36.45

67.62

30.81

EV/EBITx

—

54.94

63.41

48.45

55.63

40.12

28.41

54.94

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

7.11

EPS₹

—

12.19

11.73

8.63

5.59

7.11

7.71

(12.62%)

—

27.15

EPS growth%

—

(3.78)

(26.41)

(35.26)

27.15

8.42

(15.10)

—

Bookvalue per sh₹

—

FCF per share₹

—

1.00

Dividend per sh₹

—

1.00

1.03

—

0.36

Div yield (avg)%

—

0.12

0.11

0.17

0.19

0.27

0.37

0.17

14.07

Payout ratio%

—

8.20

8.52

11.58

17.89

14.07

13.32

11.58

—

13.56

Shares (diluted)M

—

12.22

12.65

12.66

12.71

13.56

◌13.56

2.65%

(6.67)

Buyback yield%

—

(3.56)

(0.06)

(0.44)

(6.67)

◌—

(2.00)

—

D/E ratiox

—

3.810

Enterprise value₹B

—

9.832

11.18

7.392

6.560

4.963

3.810

(15.71%)

—

LT debt₹M

—

Peers (US$39.77M)

Cap (US$)

Valiant Laboratories…

67.15M

35.96x

Albert David Limited

48.20M

19.65x

Aarey Drugs & Pharmace…

33.05M

85.43x

Solasia Pharma K.K.

39.87M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

3.537

3.736

Own earn%

—

Sh yield%

(6.32)

(1.84)

Owners

Insiders/Inst%

4.88

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

3/4

EPS growth years

1/4

Dividend streakyrs

Op margin range%

6–16

$1 testx

—

Incr. ROIC%

—

Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, and sells pharmaceutical formulations in India and internationally. The company provides tablets, capsules, dry syrups, oral liquids, ointments, and other pharmaceutical dosage forms.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹1.978B

14.41%

1.00×

Cost of revenue

₹1.045B

17.84%

1.13×

Operating expenses

₹808.9M

16.88%

1.09×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m